指南与共识心脑血管急症重症综合管理与镇静镇痛

2022年兽医重症监护中抗血栓与溶栓药物合理使用共识(CURATIVE)第6部分:溶栓药物合理使用定义

2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.
指南 / 共识 · J Vet Emerg Crit Care (San Antonio) · 2022-01-01
一句话结论犬猫动静脉血栓溶栓治疗证据不足,CURATIVE共识仅给出弱推荐性考虑,需更多以患者为中心的临床试验。

该共识由CURATIVE工作组制定,针对犬猫疑似或确诊动脉和静脉血栓的溶栓治疗,通过系统文献评价和Delphi调查形成14个PICO问题和14条指南。犬类文献多为实验研究(证据等级3),不足以确定溶栓是否改善以患者为中心的结局;猫类文献更有限且常对PICO问题持中性态度,无法形成强证据推荐。共识仅就何时可考虑溶栓药物、溶栓药与抗凝或抗血小板药联用以及溶栓药选择给出建议。结论是需要大量额外研究,以患者为中心的临床试验最有价值。

要点

  • 犬猫动静脉血栓溶栓治疗证据不足:犬类文献多为实验研究(证据等级3),无法确定溶栓是否改善患者中心结局。
  • 猫类文献更有限且常对PICO问题持中性态度,无法形成强证据推荐。
  • 共识仅就溶栓药物考虑时机、与抗凝或抗血小板药联用及溶栓药选择给出建议,未形成强推荐。
  • 需大量额外研究,以患者为中心的临床试验最有价值。

适用人群与场景

  • 犬和猫(分别考虑)的动脉和静脉血栓,疑似或确诊血栓形成。

研究设计与关键结果

  • 制定机构:CURATIVE工作组;方法:系统文献评价,PICO问题制定和工作表完成,Delphi调查精炼指南;形成14个PICO问题和14条指南。
  • 犬类文献多为实验研究(证据等级3),不足以确定溶栓是否改善以患者为中心的结局;猫类文献更有限且常对PICO问题持中性态度,无法形成强证据推荐。
  • 共识就溶栓药物考虑时机、与抗凝或抗血小板药联用及溶栓药选择给出建议。

证据类型、等级与局限

  • 证据类型:指南/共识;证据等级:犬类文献多为实验研究(证据等级3);猫类文献更有限且常对PICO问题持中性态度。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 原文未据此给出推荐,仅复述:犬猫动静脉血栓溶栓治疗证据不足,共识仅给出考虑性建议,需更多以患者为中心的临床试验。

指南或共识出处

  • 指南名称:2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics;发布机构:CURATIVE工作组;年份:2022。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To systematically review available evidence and establish guidelines related to the use of thrombolytics for the management of small animals with suspected or confirmed thrombosis.

DESIGN: PICO (Population, Intervention, Control, and Outcome) questions were formulated, and worksheets completed as part of a standardized and systematic literature evaluation. The population of interest included dogs and cats (considered separately) and arterial and venous thrombosis. The interventions assessed were the use of thrombolytics, compared to no thrombolytics, with or without anticoagulants or antiplatelet agents. Specific protocols for recombinant tissue plasminogen activator were also evaluated. Outcomes assessed included efficacy and safety. Relevant articles were categorized according to level of evidence, quality, and as to whether they supported, were neutral to, or opposed the PICO questions. Conclusions from the PICO worksheets were used to draft guidelines, which were subsequently refined via Delphi surveys undertaken by the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) working group.

RESULTS: Fourteen PICO questions were developed, generating 14 guidelines. The majority of the literature addressing the PICO questions in dogs is experimental studies (level of evidence 3), thus providing insufficient evidence to determine if thrombolysis improves patient-centered outcomes. In cats, literature was more limited and often neutral to the PICO questions, precluding strong evidence-based recommendations for thrombolytic use. Rather, for both species, suggestions are made regarding considerations for when thrombolytic drugs may be considered, the combination of thrombolytics with anticoagulant or antiplatelet drugs, and the choice of thrombolytic agent.

CONCLUSIONS: Substantial additional research is needed to address the role of thrombolytics for the treatment of arterial and venous thrombosis in dogs and cats. Clinical trials with patient-centered outcomes will be most valuable for addressing knowledge gaps in the field.

来源:J Vet Emerg Crit Care (San Antonio),查看原文。版权归原作者所有。

参考来源

  1. Sharp CR, Blais MC, Boyd CJ, et al. 2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics. J Vet Emerg Crit Care (San Antonio). 2022. PMID: 35881647. doi:10.1111/vec.13227

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。